background: because of the reported poor prognosis and absence of effective and specific therapeutic approaches, triple-negative breast cancer (tnbc) tumors have remained as an important area of investigations for clinicians and researchers. the aim of this study was to determine the clinical, pathological, histological, prognostic features, and outcome associated with this type of breast cance...

Abstract Background PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients with BRCA mutations, and their efficacy is even more limited in triple-negative (TNBC) due to clinical primary acquired resistance. Here, we found that the PARPi olaparib TNBC can be improved by combination CDK4/6 inhibitor (CDK4/6i) palbociclib. Methods We screened olaparib-sensitive olaparib-resistan...

The efficacy of neoadjuvant chemotherapy (NAC), as measured by the pathological complete response (pCR), varies between molecular subtypes in breast cancer (BC). Oestrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative patients tend to have lower pCR rates. transcription progesterone (PR) is dependent on ER therefore PR negativity may suggest an erroneous oestrogen sign...

background : triple-negative breast cancers (tnbc) are defined as breast cancers with lack of estrogen and progesterone receptors and no overexpression of human epidermal growth factor receptor 2 (her2). this study was performed to determine the frequency and pathologic features of tnbc in iranian patients. subjects and methods: this cross-sectional study was performed on patients with breast c...

Background: Triple Negative Breast Carcinomas (TNBC) are breast carcinomas which negative for Estrogen receptor (ER) Progesterone (PR) and no overexpression of Human Epidermal Growth Factor receptor-2 (HER-2). The five-year survival rate in general is good but the same bad TNBC. TNBC has got worse prognosis compared to hormone positive carcinomas. Aim: aim present study compare invasive lobular...

Background: The study aimed to identify and target effects associated with HORMAD1 expression in breast cancer cells. Materials methods: Isogenic cell line models inducible were used dependencies induced by expression. Results: Expression of HORMAD1, a gene whose function is best understood meiosis, usually restricted germ-line cells but becomes aberrantly expressed 60% triple-negative cancers ...

Abstract Triple negative breast cancer (TNBC) is an aggressive subset with poor outcomes. TNBCs do not express the estrogen, progesterone, or HER2 receptors and are thus candidates for antiestrogen anti-HER2 therapies, leaving few effective treatments. One therapeutic strategy to target molecular components of individual patient’s cancer. Prior work in our group has nominated monopolar spindle ...

Although triple negative breast cancers (TNBC) are the most aggressive subtype of breast cancer, they currently lack targeted therapies. Because this classification still includes a heterogeneous collection of tumors, new tools to classify TNBCs are urgently required in order to improve our prognostic capability for high risk patients and predict response to therapy. We previously defined a gen...

Background: Triple-negative breast cancers (TNBC) are defined as breast cancers with lack of estrogen and progesterone receptors and no overexpression of human epidermal growth factor receptor 2 (HER2). This study was performed to determine the frequency and pathologic features of TNBC in Iranian patients. Subjects and Methods: This cross-sectional study was performed on patients with breast ca...

UNLABELLED Triple-negative (ER(-), HER2(-), PR(-)) breast cancer (TNBC) is an aggressive disease with a poor prognosis with no available molecularly targeted therapy. Silencing of microRNA-145 (miR-145) may be a defining marker of TNBC based on molecular profiling and deep sequencing. Therefore, the molecular mechanism behind miR-145 downregulation in TNBC was examined. Overexpression of the lo...